MCAM and melanoma: In particular we showed in A375 and HT-144 melanoma cells treated with (Bu2Sn)2TPPS, the decreased expression of integrin β1 (Figure 8A and Figure 9A, left and right panels), integrin β3 (Figure 8B and Figure 9B, left and right panels), MCAM (Figure 10A,B, left and right panels) and ICAM (Figure 10C,D, left and right panels) adhesion receptors, with the exception of the steady state level expression of integrin β3 after 72 h of treatment in both cell lines (Figure 8B and Figure 9B, left and right panels), compared to untreated cells (NT).